NDRA Q3'26 Earnings: EPS estimate is (0.84) USD

ENDRA Life Sciences Inc. (NDRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 August 17, 2026 ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update ANN ARBOR, Mich., (BUSINESS WIRE) – ENDRA Life Sciences Inc . (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for e

ASP Isotopes plans to merge its subsidiary Noble Africa, which holds South Africa’s Renergen helium and LNG project, with ENDRA Life Sciences to form a publicly listed helium platform called Noble Africa. ASP Isotopes expects ~89% ownership post-close. Management cites 1P helium reserves of 7.2 Bcf and targets Phase 1 output of ~70 Mcf/day helium and 2,500 GJ/day LNG, with estimated revenue and cash gross profit. Closing is targeted for Q4, subject to SEC review and approvals.

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.